Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology

• DOI: 10.1007/s10147-019-01610-y
• Publication Date: 2020-01-24T05:05:44Z
• Authors: Yoichi Naito; Saori Mishima; Kiwamu Akagi; Ataru Igarashi; Masafumi Ikeda; Susumu Okano; Shunsuke Kato; Tadao Takano; Katsuya Tsuchihara; Keita Terashima; Hiroshi Nishihara; Hiroyki Nishiyama; Eiso Hiyama; Akira Hirasawa; Hajime Hosoi; Osamu Maeda; Yasushi Yatabe; Wataru Okamoto; Shigeru Ono; Hiroaki Kajiyama; Fumio Nagashima; Yutaka Hatanaka; Mitsuru Miyachi; Yasuhiro Kodera; Takayuki Yoshino; Hiroya Taniguchi
• Keywords: Guideline; Surgical oncology; Clinical Oncology; Hematology

Abstract Background The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we published provisional clinical opinion for the diagnosis use immunotherapy in patients with deficient DNA mismatch repair tumors. Recently, efficacy tropomyosin receptor kinase inhibitors against neurotrophic tyrosine (NTRK) fusion gene-positive advanced solid tumors have been established as second tumor-agnostic treatment, making it necessary to develop guideline prioritized these patients. Methods Clinical questions regarding medical care were formulated NTRK -positive Relevant publications searched by PubMed Cochrane Database. Critical conference reports added manually. Systematic reviews performed each question purpose developing recommendations. committee members identified Japan Society Oncology (JSCO) Japanese Medical (JSMO) voted determine level recommendation considering strength evidence, expected risks benefits patients, other related factors. Thereafter, a peer review experts nominated from JSCO, JSMO, Pediatric Hematology/Oncology, public comments among all Societies’ was done. Results current describes 3 15 recommendations whom, when, how should be tested, what is recommended fusion-positive Conclusion In guideline, proposed performing testing properly select who are likely benefit inhibitors.